These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27769353)

  • 21. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
    Albrecht BK; Gehling VS; Hewitt MC; Vaswani RG; Côté A; Leblanc Y; Nasveschuk CG; Bellon S; Bergeron L; Campbell R; Cantone N; Cooper MR; Cummings RT; Jayaram H; Joshi S; Mertz JA; Neiss A; Normant E; O'Meara M; Pardo E; Poy F; Sandy P; Supko J; Sims RJ; Harmange JC; Taylor AM; Audia JE
    J Med Chem; 2016 Feb; 59(4):1330-9. PubMed ID: 26815195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging roles of BET proteins in transcription and co-transcriptional RNA processing.
    Eischer N; Arnold M; Mayer A
    Wiley Interdiscip Rev RNA; 2023 Jan; 14(1):e1734. PubMed ID: 35491403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functions of BET proteins in erythroid gene expression.
    Stonestrom AJ; Hsu SC; Jahn KS; Huang P; Keller CA; Giardine BM; Kadauke S; Campbell AE; Evans P; Hardison RC; Blobel GA
    Blood; 2015 Apr; 125(18):2825-34. PubMed ID: 25696920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Segmental Isotope Labelling of an Individual Bromodomain of a Tandem Domain BRD4 Using Sortase A.
    Williams FP; Milbradt AG; Embrey KJ; Bobby R
    PLoS One; 2016; 11(4):e0154607. PubMed ID: 27128490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation.
    Shi M; He J; Weng T; Shi N; Qi W; Guo Y; Chen T; Chen L; Xu D
    Phys Chem Chem Phys; 2022 Feb; 24(8):5125-5137. PubMed ID: 35156677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1).
    Hügle M; Lucas X; Weitzel G; Ostrovskyi D; Breit B; Gerhardt S; Einsle O; Günther S; Wohlwend D
    J Med Chem; 2016 Feb; 59(4):1518-30. PubMed ID: 26731611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors.
    Zhang F; Ma S
    Curr Drug Targets; 2018; 19(10):1148-1165. PubMed ID: 29189147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails.
    Liu Y; Wang X; Zhang J; Huang H; Ding B; Wu J; Shi Y
    Biochemistry; 2008 Jun; 47(24):6403-17. PubMed ID: 18500820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advancements in the Development of non-BET Bromodomain Chemical Probes.
    Clegg MA; Tomkinson NCO; Prinjha RK; Humphreys PG
    ChemMedChem; 2019 Feb; 14(4):362-385. PubMed ID: 30624862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4.
    Bai P; Lan Y; Wang H; Liu Y; Striar R; Yuan G; Afshar S; Zagaroli JS; Tocci DR; Langan AG; Wang C
    Bioconjug Chem; 2021 Aug; 32(8):1711-1718. PubMed ID: 34139120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiosynthesis and in vivo evaluation of a new positron emission tomography radiotracer targeting bromodomain and extra-terminal domain (BET) family proteins.
    Bai P; Lu X; Lan Y; Chen Z; Patnaik D; Fiedler S; Striar R; Haggarty SJ; Wang C
    Nucl Med Biol; 2020; 84-85():96-101. PubMed ID: 32320910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Research Advances in the Mechanisms of BRD4 and Its Inhibitors in Hematologic Malignancies--Review].
    Gao RL; Zeng CW; Li YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1365-1368. PubMed ID: 34362532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRD4 in physiology and pathology: ''BET'' on its partners.
    Liang Y; Tian J; Wu T
    Bioessays; 2021 Dec; 43(12):e2100180. PubMed ID: 34697817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics.
    Cai M; Dong J; Li H; Qin JJ
    Curr Med Chem; 2022; 29(25):4391-4409. PubMed ID: 35152859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure of the Brd4 ET domain bound to a C-terminal motif from γ-retroviral integrases reveals a conserved mechanism of interaction.
    Crowe BL; Larue RC; Yuan C; Hess S; Kvaratskhelia M; Foster MP
    Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2086-91. PubMed ID: 26858406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
    Jones KL; Beaumont DM; Bernard SG; Bit RA; Campbell SP; Chung CW; Cutler L; Demont EH; Dennis K; Gordon L; Gray JR; Haase MV; Lewis AJ; McCleary S; Mitchell DJ; Moore SM; Parr N; Robb OJ; Smithers N; Soden PE; Suckling CJ; Taylor S; Walker AL; Watson RJ; Prinjha RK
    J Med Chem; 2021 Aug; 64(16):12200-12227. PubMed ID: 34387088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer.
    Zhu L; Ding X
    J Mol Recognit; 2018 Feb; 31(2):. PubMed ID: 28983974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
    Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.